Im having trouble understanding this paper: https://www.ncbi.nlm.nih.gov/pubmed/26142652
Title of the paper is Pharmacological Modulation of the Mitochondrial Electron Transport Chain in Paclitaxel-Induced Painful Peripheral Neuropathy
Why did she choose an inhibitor for a mitochondria disfunction. Im thinking about competive binding, because only before and during the administration the desired effect took place. But in the paper they never talked about competive binding. So can someone please give me more insights about this subject.